{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T06:24:20Z","timestamp":1789453460023,"version":"build-2803163510"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,8,18]]},"DOI":"10.7759\/cureus.67151","type":"journal-article","created":{"date-parts":[[2024,8,19]],"date-time":"2024-08-19T04:15:20Z","timestamp":1724040920000},"source":"Crossref","is-referenced-by-count":2,"title":["Evaluating Bempedoic Acid for Non-alcoholic Fatty Liver Disease: A Review of Preclinical and Clinical Research"],"prefix":"10.7759","author":[{"given":"Mohamed","family":"Anasdeen S","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahinaz","family":"S","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijayakumar","family":"TM","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"Non-alcoholic fatty liver disease. global scenario, challenges, and preparedness. (2023). Accessed: August 17, 2024: https:\/\/www.worldgastroenterology.org\/publications\/e-wgn\/e-wgn-expert-point-of-view-articles-collection\/non-alcoholic...."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-019-0144-8","article-title":"Past, present and future perspectives in nonalcoholic fatty liver disease","volume":"16","author":"Sanyal AJ","year":"2019","unstructured":"Sanyal AJ. Past, present and future perspectives in nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol. 2019, 16:377-86. 10.1038\/s41575-019-0144-8","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-018-2947-0","article-title":"Molecular pathways of nonalcoholic fatty liver disease development and progression","volume":"76","author":"Bessone F","year":"2019","unstructured":"Bessone F, Razori MV, Roma MG. Molecular pathways of nonalcoholic fatty liver disease development and progression. Cell Mol Life Sci. 2019, 76:99-128. 10.1007\/s00018-018-2947-0","journal-title":"Cell Mol Life Sci"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2008.03.078","article-title":"Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled fatty liver improvement with rosiglitazone therapy (FLIRT) trial","volume":"135","author":"Ratziu V","year":"2008","unstructured":"Ratziu V, Giral P, Jacqueminet S, et al.. Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled fatty liver improvement with rosiglitazone therapy (FLIRT) trial. Gastroenterology. 2008, 135:100-10. 10.1053\/j.gastro.2008.03.078","journal-title":"Gastroenterology"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2008.06.047","article-title":"Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis","volume":"135","author":"Aithal GP","year":"2008","unstructured":"Aithal GP, Thomas JA, Kaye PV, et al.. Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. Gastroenterology. 2008, 135:1176-84. 10.1053\/j.gastro.2008.06.047","journal-title":"Gastroenterology"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1111\/1751-2980.13210","article-title":"Vitamin E supplementation in the treatment on nonalcoholic fatty liver disease (NAFLD): evidence from an umbrella review of meta-analysis on randomized controlled trials","volume":"24","author":"Wang MY","year":"2023","unstructured":"Wang MY, Prabahar K, G\u0103man MA, Zhang JL. Vitamin E supplementation in the treatment on nonalcoholic fatty liver disease (NAFLD): evidence from an umbrella review of meta-analysis on randomized controlled trials. J Dig Dis. 2023, 24:380-9. 10.1111\/1751-2980.13210","journal-title":"J Dig Dis"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.790","article-title":"Pharmacokinetics and pharmacodynamics of ursodeoxycholic acid in an overweight population with abnormal liver function","volume":"10","author":"Yoon S","year":"2021","unstructured":"Yoon S, Lee H, Ji SC, Yoon SH, Cho JY, Chung JY. Pharmacokinetics and pharmacodynamics of ursodeoxycholic acid in an overweight population with abnormal liver function. Clin Pharmacol Drug Dev. 2021, 10:68-77. 10.1002\/cpdd.790","journal-title":"Clin Pharmacol Drug Dev"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)33041-7","article-title":"Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial","volume":"394","author":"Younossi ZM","year":"2019","unstructured":"Younossi ZM, Ratziu V, Loomba R, et al.. Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. Lancet. 2019, 394:2184-96. 10.1016\/S0140-6736(19)33041-7","journal-title":"Lancet"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.7b00907","article-title":"Discovery of tropifexor (LJN452), a highly potent non-bile acid FXR agonist for the treatment of cholestatic liver diseases and nonalcoholic steatohepatitis (NASH)","volume":"60","author":"Tully DC","year":"2017","unstructured":"Tully DC, Rucker PV, Chianelli D, et al.. Discovery of tropifexor (LJN452), a highly potent non-bile acid FXR agonist for the treatment of cholestatic liver diseases and nonalcoholic steatohepatitis (NASH). J Med Chem. 2017, 60:9960-73. 10.1021\/acs.jmedchem.7b00907","journal-title":"J Med Chem"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2306185","article-title":"Efficacy and safety of elafibranor in primary biliary cholangitis","volume":"390","author":"Kowdley KV","year":"2024","unstructured":"Kowdley KV, Bowlus CL, Levy C, et al.. Efficacy and safety of elafibranor in primary biliary cholangitis. N Engl J Med. 2024, 390:795-805. 10.1056\/NEJMoa2306185","journal-title":"N Engl J Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1002\/hep.31843","article-title":"Saroglitazar, a PPAR-\u03b1\/\u03b3 agonist, for treatment of NAFLD: a randomized controlled double-blind phase 2 trial","volume":"74","author":"Gawrieh S","year":"2021","unstructured":"Gawrieh S, Noureddin M, Loo N, et al.. Saroglitazar, a PPAR-\u03b1\/\u03b3 agonist, for treatment of NAFLD: a randomized controlled double-blind phase 2 trial. Hepatology. 2021, 74:1809-24. 10.1002\/hep.31843","journal-title":"Hepatology"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-024-02045-0","article-title":"Resmetirom: first approval","volume":"84","author":"Keam SJ","year":"2024","unstructured":"Keam SJ. Resmetirom: first approval. Drugs. 2024, 84:729-35. 10.1007\/s40265-024-02045-0","journal-title":"Drugs"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2023.101193","article-title":"Combination of an ACLY inhibitor with a GLP-1R agonist exerts additive benefits on nonalcoholic steatohepatitis and hepatic fibrosis in mice","volume":"4","author":"Desjardins EM","year":"2023","unstructured":"Desjardins EM, Wu J, Lavoie DC, et al.. Combination of an ACLY inhibitor with a GLP-1R agonist exerts additive benefits on nonalcoholic steatohepatitis and hepatic fibrosis in mice. Cell Rep Med. 2023, 4:101193. 10.1016\/j.xcrm.2023.101193","journal-title":"Cell Rep Med"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.116.308963","article-title":"Prevention of diet-induced metabolic dysregulation, inflammation, and atherosclerosis in Ldlr-\/- mice by treatment with the ATP-citrate lyase inhibitor bempedoic acid","volume":"37","author":"Samsoondar JP","year":"2017","unstructured":"Samsoondar JP, Burke AC, Sutherland BG, et al.. Prevention of diet-induced metabolic dysregulation, inflammation, and atherosclerosis in Ldlr-\/- mice by treatment with the ATP-citrate lyase inhibitor bempedoic acid. Arterioscler Thromb Vasc Biol. 2017, 37:647-56. 10.1161\/ATVBAHA.116.308963","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.117.310676","article-title":"Bempedoic acid lowers low-density lipoprotein cholesterol and attenuates atherosclerosis in low-density lipoprotein receptor-deficient (LDLR+\/- and LDLR-\/-) Yucatan miniature pigs","volume":"38","author":"Burke AC","year":"2018","unstructured":"Burke AC, Telford DE, Sutherland BG, et al.. Bempedoic acid lowers low-density lipoprotein cholesterol and attenuates atherosclerosis in low-density lipoprotein receptor-deficient (LDLR+\/- and LDLR-\/-) Yucatan miniature pigs. Arterioscler Thromb Vasc Biol. 2018, 38:1178-90. 10.1161\/ATVBAHA.117.310676","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms13457","article-title":"Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis","volume":"7","author":"Pinkosky SL","year":"2016","unstructured":"Pinkosky SL, Newton RS, Day EA, et al.. Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis. Nat Commun. 2016, 7:13457. 10.1038\/ncomms13457","journal-title":"Nat Commun"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2018.06.002","article-title":"Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: a randomized, placebo-controlled study","volume":"277","author":"Ballantyne CM","year":"2018","unstructured":"Ballantyne CM, Banach M, Mancini GB, Lepor NE, Hanselman JC, Zhao X, Leiter LA. Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: a randomized, placebo-controlled study. Atherosclerosis. 2018, 277:195-203. 10.1016\/j.atherosclerosis.2018.06.002","journal-title":"Atherosclerosis"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2019.06.020","article-title":"Efficacy and safety of bempedoic acid + ezetimibe fixed-dose combination in patients at high CVD risk and with elevated LDL-C receiving maximally tolerated statin therapy","volume":"287","author":"Ballantyne C","year":"2019","unstructured":"Ballantyne C, Laufs U, Ray KK, et al.. Efficacy and safety of bempedoic acid + ezetimibe fixed-dose combination in patients at high CVD risk and with elevated LDL-C receiving maximally tolerated statin therapy. Atherosclerosis. 2019, 287:7-8. 10.1016\/j.atherosclerosis.2019.06.020","journal-title":"Atherosclerosis"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2015.12.025","article-title":"Treatment with ETC-1002 alone and in combination with ezetimibe lowers LDL cholesterol in hypercholesterolemic patients with or without statin intolerance","volume":"10","author":"Thompson PD","year":"2016","unstructured":"Thompson PD, MacDougall DE, Newton RS, et al.. Treatment with ETC-1002 alone and in combination with ezetimibe lowers LDL cholesterol in hypercholesterolemic patients with or without statin intolerance. J Clin Lipidol. 2016, 10:556-67. 10.1016\/j.jacl.2015.12.025","journal-title":"J Clin Lipidol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.113.302677","article-title":"Efficacy and safety of ETC-1002, a novel investigational low-density lipoprotein-cholesterol-lowering therapy for the treatment of patients with hypercholesterolemia and type 2 diabetes mellitus","volume":"34","author":"Gutierrez MJ","year":"2014","unstructured":"Gutierrez MJ, Rosenberg NL, Macdougall DE, et al.. Efficacy and safety of ETC-1002, a novel investigational low-density lipoprotein-cholesterol-lowering therapy for the treatment of patients with hypercholesterolemia and type 2 diabetes mellitus. Arterioscler Thromb Vasc Biol. 2014, 34:676-83. 10.1161\/ATVBAHA.113.302677","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2023.06.973","article-title":"Efficacy and safety of bempedoic acid in patients with and without metabolic syndrome: pooled analysis of data from four phase 3 clinical trials","volume":"378","author":"Shapiro MD","year":"2023","unstructured":"Shapiro MD, Taub PR, Louie MJ, Lei L, Ballantyne CM. Efficacy and safety of bempedoic acid in patients with and without metabolic syndrome: pooled analysis of data from four phase 3 clinical trials. Atherosclerosis. 2023, 378:117182. 10.1016\/j.atherosclerosis.2023.06.973","journal-title":"Atherosclerosis"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/281683-evaluating-bempedoic-acid-for-non-alcoholic-fatty-liver-disease-a-review-of-preclinical-and-clinical-research","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,19]],"date-time":"2024-08-19T04:15:24Z","timestamp":1724040924000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/281683-evaluating-bempedoic-acid-for-non-alcoholic-fatty-liver-disease-a-review-of-preclinical-and-clinical-research"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,18]]},"references-count":21,"URL":"https:\/\/doi.org\/10.7759\/cureus.67151","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8,18]]}}}